Cargando…
Vogt-Koyanagi-Harada Disease and COVID
Vogt–Koyanagi–Harada (VKH) is a rare multisystem inflammatory disease affecting the eyes, ears, brain, skin, and hair. The Coronavirus Disease 2019 (COVID-19) is a new contagious infection that might trigger the onset of VKH disease, as previously proposed for other viruses. Moreover, after the mass...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573236/ https://www.ncbi.nlm.nih.gov/pubmed/37834885 http://dx.doi.org/10.3390/jcm12196242 |
_version_ | 1785120416363184128 |
---|---|
author | Manni, Priscilla Saturno, Maria Carmela Accorinti, Massimo |
author_facet | Manni, Priscilla Saturno, Maria Carmela Accorinti, Massimo |
author_sort | Manni, Priscilla |
collection | PubMed |
description | Vogt–Koyanagi–Harada (VKH) is a rare multisystem inflammatory disease affecting the eyes, ears, brain, skin, and hair. The Coronavirus Disease 2019 (COVID-19) is a new contagious infection that might trigger the onset of VKH disease, as previously proposed for other viruses. Moreover, after the mass vaccination against SARS-CoV-2 worldwide, cases of VKH disease associated with COVID-19 vaccination have been reported. We present an overview of VKH and a comprehensive literature revision of all the VKH cases described after COVID-19 infection and vaccination, adding our experience. No differences have been found considering epidemiology and clinical findings of the disease compared to those reported in the no-COVID era. All of the patients promptly responded to systemic and local corticosteroid therapy with a good final visual prognosis. Different possible pathogenetic mechanisms underlying the onset of VKH after COVID-19 vaccination are discussed, while the presence of the HLA DR4 antigen as a genetic predisposition for the onset of the disease after COVID-19 infection and vaccination is proposed. VKH disease is one of the most frequently reported uveitic entities after COVID-19 vaccination, but a good response to therapy should not discourage vaccination. Nevertheless, ophthalmologists should be alerted to the possibility of VKH occurrence or relapse after COVID-19 vaccination, especially in genetically predisposed subjects. |
format | Online Article Text |
id | pubmed-10573236 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105732362023-10-14 Vogt-Koyanagi-Harada Disease and COVID Manni, Priscilla Saturno, Maria Carmela Accorinti, Massimo J Clin Med Review Vogt–Koyanagi–Harada (VKH) is a rare multisystem inflammatory disease affecting the eyes, ears, brain, skin, and hair. The Coronavirus Disease 2019 (COVID-19) is a new contagious infection that might trigger the onset of VKH disease, as previously proposed for other viruses. Moreover, after the mass vaccination against SARS-CoV-2 worldwide, cases of VKH disease associated with COVID-19 vaccination have been reported. We present an overview of VKH and a comprehensive literature revision of all the VKH cases described after COVID-19 infection and vaccination, adding our experience. No differences have been found considering epidemiology and clinical findings of the disease compared to those reported in the no-COVID era. All of the patients promptly responded to systemic and local corticosteroid therapy with a good final visual prognosis. Different possible pathogenetic mechanisms underlying the onset of VKH after COVID-19 vaccination are discussed, while the presence of the HLA DR4 antigen as a genetic predisposition for the onset of the disease after COVID-19 infection and vaccination is proposed. VKH disease is one of the most frequently reported uveitic entities after COVID-19 vaccination, but a good response to therapy should not discourage vaccination. Nevertheless, ophthalmologists should be alerted to the possibility of VKH occurrence or relapse after COVID-19 vaccination, especially in genetically predisposed subjects. MDPI 2023-09-27 /pmc/articles/PMC10573236/ /pubmed/37834885 http://dx.doi.org/10.3390/jcm12196242 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Manni, Priscilla Saturno, Maria Carmela Accorinti, Massimo Vogt-Koyanagi-Harada Disease and COVID |
title | Vogt-Koyanagi-Harada Disease and COVID |
title_full | Vogt-Koyanagi-Harada Disease and COVID |
title_fullStr | Vogt-Koyanagi-Harada Disease and COVID |
title_full_unstemmed | Vogt-Koyanagi-Harada Disease and COVID |
title_short | Vogt-Koyanagi-Harada Disease and COVID |
title_sort | vogt-koyanagi-harada disease and covid |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573236/ https://www.ncbi.nlm.nih.gov/pubmed/37834885 http://dx.doi.org/10.3390/jcm12196242 |
work_keys_str_mv | AT mannipriscilla vogtkoyanagiharadadiseaseandcovid AT saturnomariacarmela vogtkoyanagiharadadiseaseandcovid AT accorintimassimo vogtkoyanagiharadadiseaseandcovid |